

# Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patients

No registrations found.

|                              |                            |
|------------------------------|----------------------------|
| <b>Ethical review</b>        | Positive opinion           |
| <b>Status</b>                | Recruiting                 |
| <b>Health condition type</b> | -                          |
| <b>Study type</b>            | Observational non invasive |

## Summary

### ID

NL-OMON24467

### Source

NTR

### Brief title

CIRCUS Study

### Health condition

metastatic prostate cancer

## Sponsors and support

**Primary sponsor:** Erasmus Medical Center

**Source(s) of monetary or material Support:** Erasmus Medical Center

## Intervention

## Outcome measures

### Primary outcome

The rate of mPC patients with quantifiable ctDNA taken pre-treatment.

### Secondary outcome

- The percentage of blood samples with sufficient ctDNA.
- The interval between detected ctDNA and PSA response during treatment.
- The correlation between ctDNA response and progression-free survival.

## Study description

### Study objective

With the quantification of circulating tumor DNA treatment response assessment will improve in metastatic prostate cancer patients.

### Study design

Enrolment should be completed within 3 years.

### Intervention

Repeated blood draws and urine collection

## Contacts

### Public

afdeling Interne Oncologie - Erasmus MC Kanker Instituut, kamer Be-414a

L.F. van Dessel  
Postbus 2040

Rotterdam 3000 CA  
The Netherlands  
Tel.: 010-7044375

### Scientific

afdeling Interne Oncologie - Erasmus MC Kanker Instituut, kamer Be-414a

L.F. van Dessel  
Postbus 2040

Rotterdam 3000 CA  
The Netherlands  
Tel.: 010-7044375

## Eligibility criteria

### Inclusion criteria

- Histologically or cytologically confirmed adenocarcinoma of the prostate.
- Measurable metastatic lesion(s) according to PCWG2 and/or RECIST 1.1 criteria
- Intention to start (new) line of systemic treatment
- Written informed consent
- Willingness and capacity to follow the protocol specified visits for blood sampling for the total duration of the study.
- Age  $\geq 18$  years.
- WHO performance status  $\leq 2$ .
- Concurrent participation in CPCT-02 study

### Exclusion criteria

NA

## Study design

### Design

|                     |                            |
|---------------------|----------------------------|
| Study type:         | Observational non invasive |
| Intervention model: | Other                      |
| Masking:            | Open (masking not used)    |
| Control:            | N/A , unknown              |

### Recruitment

|                     |            |
|---------------------|------------|
| NL                  |            |
| Recruitment status: | Recruiting |

|                           |             |
|---------------------------|-------------|
| Start date (anticipated): | 08-04-2016  |
| Enrollment:               | 95          |
| Type:                     | Anticipated |

## Ethics review

|                   |                  |
|-------------------|------------------|
| Positive opinion  |                  |
| Date:             | 31-03-2016       |
| Application type: | First submission |

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

| Register | ID             |
|----------|----------------|
| NTR-new  | NL5625         |
| NTR-old  | NTR5732        |
| Other    | : MEC-2016-081 |

## Study results